CD163 and non-small cell lung carcinoma: Clinical cohort studies have also demonstrated that increased total TAM density in NSCLC tissues and elevated ratios of the M2 marker CD163 to the pan‐macrophage marker CD68 (i.e., CD163/CD68 ratio) are associated with advanced tumor stage, higher metastatic risk, and poor prognosis.